Loading...
•
Dec 31, 2021
TransMedics Q4 2021 Earnings Report
TransMedics' financial performance for Q4 2021 and full year 2021 was reported, highlighted by revenue growth and strategic advancements.
Key Takeaways
TransMedics reported a 27% increase in net revenue for Q4 2021, reaching $9.7 million, driven by the commercial launch of OCS Heart and OCS Liver in the United States. The gross margin improved to 72%, but the net loss increased to $12.7 million due to higher operating expenses related to the National OCS Program and commercialization efforts.
Net revenue reached $9.7 million, a 27% increase compared to Q4 2020.
Gross margin improved to 72% compared to 63% in Q4 2020.
Operating expenses increased to $18.3 million due to investments in the National OCS Program.
Net loss was $12.7 million, compared to $6.3 million in Q4 2020.
Forward Guidance
TransMedics anticipates net revenue for the full year 2022 to be in the range of $49 million to $55 million, representing a 62% to 82% growth compared to the previous year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...